PT-141, also known as Bremelanotide, should be reviewed as a specification-driven B2B sourcing project. Buyers comparing suppliers should confirm product identity, sourcing format, analytical documentation, quote unit, MOQ, lead time, packaging scope, and destination-market responsibilities before issuing an RFQ or placing a first order.
This guide is written for distributors, private label brand owners, OEM project teams, formulation consultants, and procurement buyers evaluating PT-141 / Bremelanotide in bulk powder, lyophilized vial, or custom fill project formats.
It covers sourcing format selection, specification fields, documentation review, MOQ logic, lead time factors, quote basis, supplier qualification checkpoints, and WUMO's project discussion support for qualified B2B inquiries.
This article is not medical advice and does not provide dosing, administration, end-use, therapeutic, clinical, or outcome guidance.
PT-141 / Bremelanotide: Sourcing Context and Specification Overview
PT-141, also known by the INN Bremelanotide, is commonly referenced in peptide sourcing and chemical documentation contexts by the CAS number 189691-06-3. It is generally described as a synthetic cyclic heptapeptide.
For B2B sourcing review, buyers should treat PT-141 / Bremelanotide as a specification-controlled peptide material. The key sourcing question is not only whether a supplier lists the SKU, but whether the supplier can define the material clearly and support the batch with appropriate documentation.
Common identification fields include:
- Peptide name: PT-141 / Bremelanotide.
- CAS number: 189691-06-3.
- Molecular formula: C50H68N14O10.
- Molecular weight: approximately 1025.2 g/mol, depending on form and supplier documentation.
- Structure reference: cyclic peptide.
- Appearance: commonly supplied as white to off-white lyophilized powder.
- Common B2B formats: bulk powder and lyophilized vial.
These identification fields should be confirmed against the supplier's specification sheet, COA, HPLC report, and LC-MS or mass confirmation where available. Name matching alone is not enough for supplier qualification.
Sourcing Format Decision: Bulk Powder vs Lyophilized Vial
Bulk powder format
Bulk powder is usually the preferred format when the buyer needs material for downstream processing, specification review, custom fill discussion, or larger-volume sourcing evaluation.
In B2B discussions, bulk PT-141 / Bremelanotide may be quoted in milligrams or grams depending on order size and supplier practice. The quotation should state net weight, purity threshold, documentation scope, MOQ, lead time, and shipment assumptions.
Bulk powder may be suitable when:
- The buyer has downstream filling or formulation capability.
- The project requires custom fill amounts.
- The buyer wants to separate material cost from vialing and packaging cost.
- The sourcing comparison is being made at peptide-content level.
- A custom lyophilized vial project will be scoped later.
A bulk powder quotation should not be compared directly with a finished vial quotation unless the buyer separates material cost, filling service, packaging, documentation, and shipping scope.
Lyophilized vial format
Lyophilized vial format is relevant when the buyer needs a vial-based project format rather than loose bulk material.
A vial quote should always specify:
- Fill amount per vial.
- Vial size.
- Vial component scope.
- Label scope.
- Vials per box where applicable.
- Documentation package.
- MOQ.
- Lead time.
- Quote unit.
PT-141 / Bremelanotide vial fill amounts are not standardized across suppliers. A lower USD/vial quote may reflect a smaller fill amount rather than a better price. Buyers should normalize quotes to peptide content basis, such as USD/mg or USD/g, before comparing suppliers.
For a broader review of vial project scoping, see WUMO's lyophilized peptide vial sourcing guide.
Custom fill and private label discussion
Custom fill means the buyer specifies fill amount, vial format, label scope, and packaging requirements before production. Private label discussion may include buyer-supplied label artwork, outer box design, neutral label options, or project-specific packaging requirements.
Custom fill and private label projects usually require more specification work than catalog vial supply. Buyers should expect a specification alignment step before formal quotation.
Custom fill discussions may include:
- Target fill amount.
- Vial size and component preference.
- Neutral or private label format.
- Box or kit composition.
- MOQ.
- Lead time.
- Documentation package.
- Artwork or label proof requirements.
- Shipment and destination-market considerations.
A private label discussion should not begin with price alone. The buyer should first define the product specification and documentation requirements.
PT-141 / Bremelanotide Specification Fields to Review Before Sourcing
Before requesting price, buyers should define the PT-141 / Bremelanotide specification fields they want suppliers to quote against.
Important fields include:
- Peptide name and naming consistency.
- CAS number.
- Molecular formula.
- Molecular weight.
- Structural reference.
- Appearance.
- Purity specification.
- Analytical method.
- Water content where applicable.
- Residual solvent limits where applicable.
- Storage condition.
- Packaging format.
- Shelf-life or retest statement where available.
The specification sheet should be reviewed before the COA whenever possible. The specification sheet defines the expected standard; the COA reports the batch result against that standard.
For a cyclic peptide, identity confirmation may require closer review than a simple name match. Buyers should confirm whether LC-MS or another mass confirmation document is available and whether the observed mass aligns with the theoretical reference used in the specification.
If any field is missing or inconsistent, the buyer should request clarification before comparing the quote with another supplier.
Documentation Package: What to Request for PT-141 / Bremelanotide
Certificate of Analysis
A batch-specific COA is the central document for peptide supplier review. For PT-141 / Bremelanotide, buyers should confirm that the COA references the specific batch being quoted or shipped.
A useful COA may include:
- Peptide name.
- Batch number.
- Appearance.
- Purity result.
- Test method.
- Molecular weight or identity reference where applicable.
- Water content where applicable.
- Storage condition.
- Analysis date.
- Issuing entity.
A generic COA without batch number has limited traceability value. The COA batch number should match the HPLC report, LC-MS report where available, label, packing list, and physical shipment.
HPLC purity report
An HPLC report supports the purity result shown on the COA. It should ideally include chromatogram, purity figure, peak integration, test date, method information, and batch reference.
Buyers should check:
- Does the HPLC report show the same batch number as the COA?
- Is a chromatogram provided, not only a purity percentage?
- Is the stated purity threshold consistent with the project specification?
- Is the report batch-specific or representative?
- Does the purity figure align with the COA?
A supplier's catalog purity claim should not be treated as equivalent to a batch-specific HPLC result.
LC-MS or mass confirmation
LC-MS or mass spectrometry confirmation helps support molecular identity review. For cyclic peptides such as PT-141 / Bremelanotide, mass confirmation can add value during new supplier qualification or higher-value project review.
A useful mass confirmation document may include:
- Observed mass.
- Theoretical mass.
- Spectrum or method reference.
- Batch or sample reference.
- Test date.
LC-MS may not be included by default for every supplier or every batch. Its absence does not automatically disqualify a supplier, but the buyer should understand whether it can be requested and whether it relates to the supplied batch.
SDS
The Safety Data Sheet supports safety, handling, storage, and transport review. It does not confirm peptide identity or purity.
Buyers should confirm that the SDS:
- Is current.
- Reflects the correct material form.
- Uses a recognizable safety data sheet structure.
- Includes handling and storage information.
- Includes transport information where applicable.
- Can support internal safety and logistics review.
The SDS should be reviewed with the shipment and storage plan, especially for international orders.
Specification sheet
The specification sheet is the quality basis for quotation and supplier comparison. It should define the standard the supplier commits to supply against.
For PT-141 / Bremelanotide, a specification sheet may include:
- Product name.
- CAS number.
- Molecular formula.
- Molecular weight.
- Structural reference.
- Appearance.
- Purity specification.
- Analytical method.
- Water content where applicable.
- Residual solvent limits where applicable.
- Storage condition.
- Packaging format.
- Shelf-life or retest statement where available.
The specification sheet and COA should align. If the COA reports fields that are not defined in the specification sheet, or the specification sheet defines fields not tested in the COA, the buyer should request clarification.
For a broader documentation review method, see WUMO's research-grade peptide shipment documents checklist.
MOQ Considerations for PT-141 / Bremelanotide
MOQ depends on sourcing format, order size, supplier setup, and project scope.
For bulk powder, MOQ may be discussed in milligrams or grams. For lyophilized vials, MOQ may be based on vial count, batch size, or project setup. For custom fill or private label projects, MOQ may be higher because the supplier must allocate production, filling, packaging, documentation, and coordination resources.
Buyers should clarify:
- Is the MOQ based on grams, vials, boxes, batch size, or order value?
- Is the MOQ for sample, pilot order, or repeat order?
- Is custom fill MOQ different from catalog vial MOQ?
- Are volume tiers available?
- Does the quote include documentation?
- Is packaging included or separate?
- Can the supplier discuss phased ordering?
MOQ should be reviewed together with total peptide content. A smaller vial count with a higher fill amount may require more peptide material than a larger vial count with a lower fill amount.
For broader MOQ and project scale considerations, see WUMO's bulk peptide purchasing guide.
Lead Time Factors for PT-141 / Bremelanotide Sourcing Projects
Lead time should be reviewed by project type.
A catalog item in stock may move faster than a made-to-order or custom fill project. A custom vial project may require specification alignment, component availability, production scheduling, QC testing, documentation preparation, and shipment coordination.
Lead time factors may include:
- Peptide material availability.
- Whether synthesis is required.
- Bulk powder packaging.
- Vial filling.
- Lyophilization schedule.
- Label and packaging preparation.
- QC testing.
- Documentation preparation.
- Export documentation.
- Shipment method.
Cyclic peptide synthesis and QC may involve additional review compared with simpler sourcing projects. Buyers should ask whether the quoted timeline reflects the actual project scope.
Buyers should also ask whether the quoted lead time covers only production or also QC, documentation, dispatch, and shipping.
A serious quotation should state lead time assumptions in writing. Chat-based estimates are useful for early discussion, but the formal quotation should define the expected timeline more clearly.
Quote Unit Basis for PT-141 / Bremelanotide
PT-141 / Bremelanotide quotes may be provided in different unit bases depending on format.
Common quote bases include:
- USD/g for bulk powder.
- USD/mg for smaller evaluation quantities.
- USD/vial for lyophilized vial projects.
- USD/box for kit or multi-vial packaging.
- USD/project for private label or custom fill discussions where setup work is included.
Buyers should not compare these units directly. A USD/vial quote must be reviewed with fill amount. A USD/box quote must be reviewed with vials per box and box contents. A USD/g quote may exclude vialing, packaging, labeling, and shipment scope.
To compare suppliers, buyers should normalize to the same basis, such as USD/mg of PT-141 / Bremelanotide content, then separately review packaging, filling, labeling, MOQ, documentation, and lead time.
For full unit comparison logic, see WUMO's guide: Peptide Quote Units Explained: USD/g vs USD/vial vs USD/box.
Storage and Shipment Considerations
Storage and shipment requirements should be confirmed in supplier documentation before dispatch.
For PT-141 / Bremelanotide sourcing projects, buyers should review:
- Recommended storage condition.
- Moisture and light sensitivity where applicable.
- Sealed-container guidance.
- Shelf-life or retest statement where available.
- Shipment temperature recommendation.
- Export packaging.
- Packing list.
- Commercial invoice.
- Destination-country import requirements.
Low-temperature storage may be recommended for many peptide materials, but exact requirements should be confirmed from the supplier's specification sheet, label, and shipment documentation.
Cold-chain transit may be discussed for international orders, depending on project requirement, shipment duration, and supplier recommendation. Buyers should confirm shipping method with their logistics partner and supplier before dispatch.
Import classification, permits, labeling obligations, and destination-market compliance remain the buyer's responsibility.
Supplier Qualification Checkpoints for PT-141 / Bremelanotide
Supplier qualification should cover both product documentation and project capability.
Key checkpoints include:
- Batch-specific COA is available.
- HPLC report supports the COA purity result.
- LC-MS or mass confirmation is available where requested.
- SDS is current and reflects the supplied form.
- Specification sheet is available before formal order.
- Batch number is consistent across documents.
- Storage condition aligns across label and documentation.
- MOQ is stated by format and unit.
- Lead time is confirmed in writing.
- Quote basis is explicit.
- Fill amount or net weight is stated.
- Custom fill or private label scope is clearly defined.
- Communication quality is sufficient for B2B project coordination.
For a broader supplier review method, see WUMO's peptide supplier qualification checklist.
How WUMO Supports Qualified PT-141 / Bremelanotide B2B Project Discussion
WUMO supports qualified B2B buyers with PT-141 / Bremelanotide sourcing discussion, specification review, documentation review, and project quotation support.
For PT-141 / Bremelanotide projects, WUMO can help buyers clarify:
- Bulk powder or lyophilized vial format.
- Documentation scope.
- COA, HPLC, LC-MS, SDS, and specification sheet availability.
- MOQ and volume tier discussion.
- Lead time assumptions.
- Quote basis.
- Custom fill feasibility.
- Neutral label or private label discussion.
- Packaging scope.
- Project fit before formal quotation.
Availability may vary by batch, project type, destination requirement, and buyer specification. Buyers are encouraged to state format, documentation, MOQ, and packaging requirements before quotation so the project can be reviewed properly.
Frequently Asked Questions
What is PT-141 / Bremelanotide and what is its CAS number?
PT-141, also known as Bremelanotide, is a synthetic cyclic peptide commonly identified in sourcing references by CAS number 189691-06-3. For B2B procurement, buyers should verify CAS number, molecular weight, structure reference, and batch documentation against the supplier's specification sheet and COA.
What is the molecular weight of PT-141 / Bremelanotide and why does it matter for sourcing?
PT-141 / Bremelanotide is commonly referenced with a molecular weight of approximately 1025.2 g/mol. Buyers should confirm the theoretical and observed mass in supplier documentation, especially when LC-MS or mass confirmation is requested.
Why does the cyclic structure of PT-141 / Bremelanotide affect supplier qualification?
Cyclic peptide structure can make identity review more important during supplier qualification. Buyers should confirm whether the supplier can provide appropriate specification details and mass confirmation where available.
What sourcing formats is PT-141 / Bremelanotide typically available in for B2B projects?
It may be discussed in bulk powder format or lyophilized vial format depending on supplier capability and buyer project scope. Buyers should confirm whether the supplier supports bulk powder, catalog vial, custom fill, or private label discussion.
What purity threshold should I specify when sourcing PT-141 / Bremelanotide for a B2B project?
Purity threshold depends on project requirements and supplier capability. Buyers should define the required threshold in the specification sheet and confirm that the COA and HPLC report support the same standard.
What documents should accompany a bulk PT-141 / Bremelanotide powder shipment?
Common documents may include batch-specific COA, HPLC report, SDS, specification sheet, packing list, commercial invoice, and LC-MS or mass confirmation where available or requested.
What fill amounts are commonly available for lyophilized PT-141 / Bremelanotide vials?
Fill amounts are not standardized across suppliers. Buyers should specify the required fill amount in the RFQ and confirm whether the supplier offers catalog fill, custom fill, or private label vial options.
How do I compare PT-141 / Bremelanotide quotes from suppliers using different unit bases?
Normalize quotes to the same peptide-content basis, such as USD/mg or USD/g. Then compare documentation, MOQ, lead time, packaging, vial fill amount, and shipment scope separately.
What is the typical MOQ for PT-141 / Bremelanotide in lyophilized vial format?
MOQ varies by supplier, fill amount, vial format, packaging scope, and whether the project is catalog fill or custom fill. Buyers should request volume tiers rather than relying on one MOQ figure.
Why is LC-MS confirmation important for cyclic peptides such as PT-141 / Bremelanotide?
LC-MS or mass confirmation helps support molecular identity review. It is useful during new supplier qualification, custom synthesis review, or higher-value project evaluation where identity confirmation matters.
What storage conditions apply to PT-141 / Bremelanotide bulk powder and lyophilized vials?
Storage conditions should be confirmed from the supplier's specification sheet, label, and shipment documentation. Many peptide materials may require low-temperature storage, moisture control, or protection from light, but exact conditions should be batch and supplier specific.
Who is responsible for confirming PT-141 / Bremelanotide import compliance in the destination market?
The buyer is responsible for confirming import, registration, labeling, distribution, and downstream compliance obligations in the destination market. Supplier documentation supports sourcing review but does not guarantee regulatory approval or import clearance.
CTA
B2B buyers evaluating PT-141 / Bremelanotide as a sourcing project — bulk powder, lyophilized vial, or custom fill — are welcome to request WUMO's documentation scope and project capability overview.
Specification review and quotation discussion are available for qualified B2B inquiries.